1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

Journal of the American College of Cardiology

Volumn 34, Issue 3, 1999, Pages 890-911

  Ryan, Thomas J ^a   Antman, Elliott M ^a   Brooks, Neil H ^a   Califf, Robert M ^a   Hillis, L David ^a   Hiratzka, Loren F ^a   Rapaport, Elliot ^a   Riegel, Barbara ^a   Russell, Richard O ^a   Smith III, Earl E ^a   Weaver, W Douglas ^a   Gibbons, Raymond J ^a   Alpert, Joseph S ^a   Eagle, Kim A ^a   Gardner, Timothy J ^a   Garson Jr , Arthur ^a   Gregoratos, Gabriel ^a   Smith Jr , Sidney C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION;

EID: 0032882186     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00351-4     Document Type: Article

References (71)

1. Tiefenbrunn A.J., Chandra N.C., French W.J., Gore J.M., Rogers W.J. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction a report from the Second National Registry of Myocardial Infarction (NRMI-2) . J Am Coll Cardiol. 31:1998;1240-1245.
2. Suryapranata H., van't Hof A.W., Hoorntje J.C., de Boer M.J., Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 97:1998;2502-2505.
3. Shindul-Rothschild J., Berry D., Long-Middleton E. Where have all the nurses gone? Final results of our patient care survey. Am J Nurs. 96:1996;25-39.
4. Madsen J.K., Grande P., Saunamaki K., et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI) DANish trial in Acute Myocardial Infarction . Circulation. 96:1997;748-755.
5. Zabel K.M., Granger C.B., Becker R.C., et al. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction results of GUSTO-1. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries . Am Heart J. 136:1998;868-876.
6. Hirsh J., Warkentin T.E., Raschke R., et al. Heparin and low-molecular heparin mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety . Chest. 114:(Suppl):1998;489S-510S.
7. Brodie B.R., Stuckey T.D., Wall T.C., et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 32:1998;1312-1319.
8. Barron H.V., Bowlby L.J., Breen T., et al. Use of reperfusion therapy for acute myocardial infarction in the United States data from the National Registry of Myocardial Infarction 2 . Circulation. 97:1998;1150-1156.
9. Cannon C.P., Gibson C.M., McCabe C.H., et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators . Circulation. 98:1998;2805-2814.
10. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
11. Tsung S.H. Several conditions causing elevation of serum CK-MB and CK-BB. Am J Clin Pathol. 75:1981;711-715.
12. Tsung J.S., Tsung S.S. Creatine kinase isoenzymes in extracts of various human skeletal muscles. Clin Chem. 32:1986;1568-1570.
13. Adams J.E. III, Bodor G.S., Davila-Roman V.G., et al. Cardiac troponin I a marker with high specificity for cardiac injury . Circulation. 88:1993;101-106.
14. Mair J., Morandell D., Genser N., et al. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem. 41:1995;1266-1272.
15. Antman E.M., Grudzien C., Mitchell R.N., Sacks D.B. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. 133:1997;596-598.
16. Ravkilde J., Horder M., Gerhardt W., et al. Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction. Scand J Clin Lab Invest. 53:1993;677-685.
17. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 335:1996;1342-1349.
18. Ohman E.M., Armstrong P.W., Christenson R.H., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia GUSTO IIA investigators . N Engl J Med. 335:1996;1333-1341.
19. Hamm C.W., Heeschen D., Goldmann B.U., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia [abstr]. J Am Coll Cardiol. 31:1998;185A.
20. Zimmerman J., Fromm R., Meyer D., et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation. 99:1999;1671-1677.
21. Ohman E.M., Armstrong P.W., Weaver W.D., et al. Prognostic value of whole-blood qualitative troponin T testing in patients with acute myocardial infarction in the GUSTO-III trial [abstr]. Circulation. 96:1998;I-216.
22. Tanasijevic M., Cannon C.P., Wybenga D.R., et al. Myoglobin, creatinine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction results from TIMI 10A . Am Heart J. 134:1997;622-630.
23. Antman E.M., Sacks D.B., Rifai N., et al. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy . J Am Coll Cardiol. 31:1998;326-330.
24. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy investigators . [published erratum appears in N Engl J Med 1997;337:287] N Engl J Med. 336:1997;1621-1628.
25. Hochman JS, Sleeper LA, Webb JG, et al, for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. New Engl J Med 1999. In Press.
26. Weaver W.D., Simes R.J., Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction a quantitative review [published erratum appears in JAMA 1998;279:1876] . JAMA. 278:1997;2093-2098.
27. Yusuf S. Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. JAMA. 278:1997;210-211.
28. Grines C.L., Morice M.D., Mattos L., et al. A prospective multicenter trial using the JJIS heparin-coated stent for reperfusion of acute myocardial infarction [abstr]. J Am Coll Cardiol. 29:1998;289A.
29. Stone G.W. Primary stenting in acute myocardial infarction the promise and the proof . Circulation. 97:1998;2482-2485.
30. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb . N Engl J Med. 335:1996;775-782.
31. Coller B.S., Folts J.D., Smith S.R., Scudder L.E., Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors . Circulation. 80:1989;1766-1774.
32. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
33. Kong D.F., Califf R.M., Miller D.P., et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 98:1998;2829-2835.
34. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE Study . [published erratum appears in Lancet 1997;350:744] Lancet. 349:1997;1429-1435.
35. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty the EPIC investigation . N Engl J Med. 330:1994;956-961.
36. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization the EPILOG investigators . N Engl J Med. 336:1997;1689-1696.
37. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators . Circulation. 98:1998;734-741.
38. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes the PURSUIT Trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy . N Engl J Med. 339:1998;436-443.
39. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study investigators . N Engl J Med. 338:1998;1498-1505.
40. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study investigators. [published erratum appears in N Engl J Med 1998;339:415]. N Engl J Med. 338:1998;1488-1497.
41. Boden W.E., O'Rourke R.A., Crawford M.H., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial investigators . N Engl J Med. 338:1998;1785-1792.
42. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Invasive versus conservative strategies in unstable angina and non-Q wave myocardial infarction following treatment with tirofiban rationale and study design of the international TACTICS-TIMI 18 Trial: Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy: Thrombolysis in Myocardial Infarction . Am J Cardiol. 82:1998;731-736.
43. Sodi-Pallares D., Testelli M.R., Fischleder B.L. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol. 9:1962;166-181.
44. Diaz R., Paolasso E.A., Piegas L.S., et al. Metabolic modulation of acute myocardial infarction the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group . Circulation. 98:1998;2227-2234.
45. Implementing Nursing's Report Card A Study of RN Staffing, Length of Stay and Patient Outcomes . 1997;1-32 American Nurses Publishing, Washington, DC.
46. Wunderlich G.S., et al. Nursing Staff in Hospitals and Nursing Homes Is It Adequate? 1996;1-18 National Academy Press, Washington, DC.
47. Mitchell P.H., Shortell S.M. Adverse outcomes and variations in organization of care delivery. Med Care. 35:1997;NS19-NS32.
48. Aiken L.H., Sochalski J., Lake E.T. Studying outcomes of organizational change in health services. Med Care. 35:1997;NS6-NS18.
49. Topaz O., DiSciascio G., Vetrovec G.W. Acute ventricular septal rupture perspectives on the current role of ventriculography and coronary arteriography and their implication for surgical repair . Am Heart J. 120:1990;412-417.
50. Topaz O., Taylor A.L. Interventricular septal rupture complicating acute myocardial infarction from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management . Am J Med. 93:1992;683-688.
51. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 128:1998;541-544.
52. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) CAPRIE Steering Committee . Lancet. 348:1996;1329-1339.
53. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction the Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) investigators . N Engl J Med. 337:1997;1124-1130.
54. A comparison of reteplase with alteplase for acute myocardial infarction the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators . N Engl J Med. 337:1997;1118-1123.
55. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction the RAPID II investigators . Circulation. 94:1996;891-898.
56. Weitz J.I. Low-molecular-weight heparins. [published erratum appears in N Engl J Med 1997;337:1567] N Engl J Med. 337:1997;688-698.
57. Danielsson A., Raub E., Lindahl U., Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 261:1986;15467-15473.
58. Cannon C.P., Antman E.M., Crawford M.H. Heparin and low-molecular-weight heparin in acute coronary syndromes and angioplasty. Crawford M.H. Cardiology Clinics Annual of Drug Therapy . 1997;105-119 WB Saunders, Philadelphia.
59. Klein W. Low molecular weight heparin in the initial and prolonged treatment of unstable coronary artery disease the fragmin in unstable coronary heart disease study (FRIC) . [abstr] Eur Heart J. 17:(Suppl):1996;306.
60. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group . N Engl J Med. 337:1997;447-452.
61. Dose-ranging trial of enoxaparin for unstable angina results of TIMI 11A . J Am Coll Cardiol. 29:1997;1474-1482.
62. Antman EM, McCabe CH, Gurfinkel EP, et al, TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarctions (TIMI) 11B trial. Circulation 1999. In Press.
63. Hurt R.D., Sachs D.P., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 337:1997;1195-1202.
64. Soumerai S.B., McLaughlin T.J., Spiegelman D., et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121.
65. Marciniak T.A., Ellerbeck E.F., Radford M.J., et al. Improving the quality of care for Medicare patients with acute myocardial infarction results from the Cooperative Cardiovascular Project . JAMA. 279:1998;1351-1357.
66. Krumholz H.M., Radford M.J., Wang Y., et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction National Cooperative Cardiovascular Project . JAMA. 280:1998;623-629.
67. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497.
68. Gheorghiade M., Schultz L., Tilley B., Kao W., Goldstein S. Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. Am J Cardiol. 66:1990;129-133.
69. Guidelines for risk stratification after myocardial infarction. American College of Physicians. Ann Intern Med. 126:1997;556-560.
70. Peterson E.D., Shaw L.J., Califf R.M. Risk stratification after myocardial infarction. Ann Intern Med. 126:1997;561-582.
71. Cardiovascular Disease: Update on Management of Heart Failure, Acute Myocardial Infarction, and Cardiac Arrhythmias. Am Fam Physician. Monograph 1. Kansas City, Mo: American Academy of Family Physicians; 1998:1.